Table 1.
Photosensitizers approved or under clinical trials.
| Name | Ex Wave-Length (nm) | Manufacturer | Application |
|---|---|---|---|
| FIRST GENERATION PHOTOSENSITIZERS | |||
| Porfimer sodium | 630 | Axcan Pharma | PDT of esophageal cancer, lung adenocarcinoma, and endobronchial cancer |
| SECOND GENERATION PHOTOSENSITIZERS/Prodrugs | |||
| 5-aminolaevulinic acid | 635 | DUSA Stabiopharma |
PDT of mild to moderate actinic keratosis Fluorescence guided resection of glioma |
| Methyl-aminolevulinic acid | 579–670 | Galderma | PDT of non-hyperkeratotic actinic keratosis and basal cell carcinoma |
| Temoporfin | 652 | Biolitec | PDT of advanced head and neck cancer |
| Talaporfin | 664 | Meiji Seika Novartis |
PDT of early centrally located lung cancer |
| Verteporfin | 690 | Novartis | PDT of age-related macular degeneration |
| Redaporfin | 749 | Luzitin | PDT of biliary tract cancer |
| PHOTOSENSITIZERS UNDER CLINICAL INVESTIGATIONS | |||
| Fotolon | 665 | Apocare Pharma | PDT of nasopharyngeal, sarcoma |
| Hexylaminolevulinate | 635 | Photocure | PDT of HPV-induced cervical precancerous lesions and non-muscle invasive bladder cancer |
| Radachlorin | 662 | Rada-pharma | PDT of skin cancer |
| Photochlor (HTTP) | 664 | Rosewell Park | PDT of head and neck cancer |
| Padeliporfin | 762 | Negma-Lerads | PDT of prostate cancer |
| Motexafin lutetium | 732 | Pharmacyclics | PDT of coronary artery disease |
| Rostaprofin | 664 | Miravant | PDT of age-related macular degeneration |
| Talaporfin | 664 | Meiji Seika | PDT of colorectal neoplasms, liver metastasis |
| Fimaporfin | 435 | PCI Biotech | PCI of cutaneous or sub-cutaneous malignancies, cholangiocarcinoma and PCI of vaccine antigens |